Beacon of hope for XLRP patients on Phase III gene therapy success
Beacon Therapeutics will seek approval for its gene therapy, laruparetigene zovaparvovec (laru-zova), in patients with X-linked retinitis pigmentosa (XLRP) after…
News
First patient dosed in Accro Bioscience’s Phase IIb AC-101 study
Addressing the global trial enrolment challenge
Otsuka reports expanded Phase IIIb results for Simtriyo in adult ADHD
Roche seeking earlier use for Lunsumio in FL on Phase III data
Everest acquires Firma’s biometrics and data services unit
China’s NMPA clears Akeso’s AK158D1 for Phase I trial in solid tumours
Altis Labs’ AI software detected treatment benefit earlier in oncology trial
